SARS-CoV-2 viral dynamics and population pharmacokinetics of favipiravir in combination with lopinavir-ritonavir in patients with COVID-19

被引:0
|
作者
Agyeman, Akosua A. [1 ]
Brown, Li-An K. [2 ]
Guerra-Assuncao, Jose A.
Breuer, Judy [1 ,3 ]
Lowe, David M. [2 ,4 ]
Standing, Joseph F. [1 ,5 ]
机构
[1] UCL, Great Ormond St Inst Child Hlth, Infect Immun & Inflammat Res & Teaching Dept, London, England
[2] UCL, Inst Immun & Transplantat, Royal Free Campus, London, England
[3] Great Ormond St Hosp Sick Children, Dept Microbiol, London, England
[4] Royal Free London NHS Fdn Trust, Dept Clin Immunol, London, England
[5] Great Ormond St Hosp Sick Children, Dept Pharm, London, England
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P0348
引用
收藏
页码:291 / 294
页数:4
相关论文
共 50 条
  • [21] Assessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review
    Magadmi, Rania M.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (44A) : 448 - 459
  • [22] Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
    Eljaaly, Khalid
    Al-Tawfiq, Jaffar A.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 38
  • [23] High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
    Karolyi, Mario
    Omid, Sara
    Pawelka, Erich
    Jilma, Bernd
    Stimpfl, Thomas
    Schoergenhofer, Christian
    Laferl, Hermann
    Seitz, Tamara
    Traugott, Marianna
    Wenisch, Christoph
    Zoufaly, Alexander
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series
    Luo, Pan
    Zheng, Jian-Ling
    Liu, Yi
    Qiu, Lin
    Liu, Xiu-Lan
    Xue, Hui-Ying
    Liu, Dong
    Li, Juan
    CLINICAL MEDICINE, 2021, 21 (01) : E80 - E83
  • [25] Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds
    Griffin, Shaun
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 370 : m2650
  • [26] Reducing the viral load of SARS-CoV-2 in the saliva of patients with COVID-19
    Guimaraes, Taisa Coelho
    Fagundes Marques, Barbara Bruno
    de Castro, Marcelle Viana
    Secco, Daniele Angst
    Moraes Sobrino Porto, Luis Cristovao
    Monnerat Tinoco, Justine Monteiro
    Barretto Tinoco, Eduardo Muniz
    Fletcher, Paul
    Fischer, Ricardo Guimaraes
    ORAL DISEASES, 2022, 28 : 2474 - 2480
  • [27] SARS-CoV-2 VIRAL LOAD IN NEWBORNS WITH COVID-19
    Parshina, A. A.
    Moskaleva, E. V.
    Petrova, A. G.
    Rychkova, L. V.
    Ogarkov, O. B.
    Orlova, E. A.
    Vanyarkina, A. S.
    Novikova, E. A.
    Kazantseva, E. D.
    YAKUT MEDICAL JOURNAL, 2023, (01): : 63 - 66
  • [28] Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?
    Zhou, Ruihai
    EUROPEAN HEART JOURNAL, 2020, 41 (22) : 2123 - 2123
  • [29] A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 (LOTUS)
    Pouchain, Denis
    Boussageon, Remy
    Leroux, Gerard
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2020, (162): : 172 - 173
  • [30] Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19
    Hagman, Karl
    Hedenstierna, Magnus
    Widaeus, Jacob
    Arvidsson, Emelie
    Hammas, Berit
    Grillner, Lena
    Jakobsson, Jan
    Gille-Johnson, Patrik
    Ursing, Johan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2735 - 2742